In an orthotopic HCC mouse model, treatment with the glycolytic inhibitor 2-deoxy-D-glucose (2-DG) downregulated IGF2BP3 expression and improved sensitivity to Lenvatinib [147]. The gene discussed is IGF2BP3; the disease is hepatocellular carcinoma.